arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

AGENUS INC

AGEN
$8.40 ▼ -0.29 (-3.39%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
47
Health
Weak
Neutral
auto_awesome

Analytical Summary

AGENUS INC demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $347.2M
Dividend Yield —
Revenue Growth 34.4% ↘
Op. Margin 32.7% ↘
ROIC -5.3% ↗
FCF / Share $-0.75 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -0.15
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$34.52M
↑ +34.4% —
Net Income Profit after all expenses
$39.21M
— 0.0% —
Operating Margin Operating profit as % of sales
32.7%
↓ -26.7% 11th
FCF / Share Free cash flow per share
$-0.75
↑ +20.3% —
Long-Term Debt Long-term obligations
$30.07M
— -0.4% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability →
14
Returns ↓
46
Financial Health
63
Cash Quality ↑
99

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters